Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
MorphoSys
Welcome,
Profile
Billing
Logout
35 Products
110 Diseases
35 Products
100 Trials
8731 News
All trials
Active industry trials
Active owner-sponsored trials
Active trials
Export
Download options
Which format:
PDF
Excel Chart
TSV
Phase
N/A
1
2
3
4
Trials
0
12
24
36
48
60
72
84
96
108
120
Tremfya
(guselkumab) / J&J
Monjuvi
(tafasitamab-cxix) / Incyte
ianalumab
(VAY736) / Novartis
bimagrumab
(BYM338) / Eli Lilly
gantenerumab
(RG1450) / Roche, Novartis
utomilumab
(PF-05082566) / Pfizer
felzartamab
(MOR202) / Biogen
anetumab ravtansine
(BAY 94-9343) / Bayer
otilimab
(GSK3196165) / GSK
setrusumab
(UX143) / Mereo Biopharma, Ultragenyx
abelacimab
(MAA868) / Novartis
tesidolumab
(LFG316) / Novartis
xentuzumab
(BI-836845) / Boehringer Ingelheim
pelabresib
(DAK539) / Novartis
ecleralimab
(CSJ117) / Novartis
elgemtumab
(LJM-716) / Novartis
carlumab
(CNTO 888) / J&J, Novartis
CMK389
/ Novartis
JNJ-42915925
/ J&J
LKA651
/ Novartis
MOR106
/ Galapagos, Novartis
befovacimab
(BAY 1093884) / Bayer
izastobart
(HIB210) / Biogen
tulmimetostat
(DZR123) / Novartis
vantictumab
(OMP-18R5) / Mereo Biopharma
BHQ880
/ Novartis
CNTO6785
/ J&J, Fontacea
lirametostat
(CPI-1205) / Novartis
tarextumab
(OMP-59R5) / Mereo Biopharma, Novartis
BAY79-4620
/ Bayer, Pfizer, Novartis
BI-1
/ Boehringer Ingelheim
CLG561
/ Novartis
HKT288
/ Novartis
MHU650
/ Novartis
MOR107
/ Novartis
PCA062
/ Novartis
